Literature DB >> 29211921

Infections and the relationship to treatment in neuromuscular autoimmunity.

Devin E Prior1, Emily Nurre1, Stephanie L Roller1, David Kline2, Ramit Panara1, Amro M Stino1, John A Davis3, Miriam L Freimer1,4, W David Arnold1,4,5.   

Abstract

INTRODUCTION: This study aimed to identify infections in patients with myasthenia gravis, dermatomyositis, and chronic inflammatory demyelinating polyradiculoneuropathy, and to investigate the relationship between infection and immunomodulation.
METHODS: A retrospective chart review examined 631 patients with myasthenia gravis (n = 358), chronic inflammatory demyelinating polyradiculoneuropathy (n = 124), and dermatomyositis (n = 149) patients over a 10-year time period.
RESULTS: Infection rates were similar at approximately 19% in all 3 diseases. Of the infections in which a causative organism was identified, pneumonia, sepsis, and opportunistic infections were the leading diagnoses. A multivariate model demonstrated a significant association between infection and an increased dose of plasma exchange, mycophenolate mofetil, and corticosteroid therapy. DISCUSSION: There are few large studies investigating rates of infections in patients with autoimmune neuromuscular disorders and the relationship to immunomodulation. This study not only demonstrates the remarkably similar infection rates across the 3 diseases studied, but also shows their relationship to commonly used immunotherapies. Muscle Nerve 57: 927-931, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic inflammatory demyelinating polyradiculoneuropathy; dermatomyositis; immunosuppression; infection; myasthenia gravis

Mesh:

Substances:

Year:  2017        PMID: 29211921      PMCID: PMC5951723          DOI: 10.1002/mus.26032

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  20 in total

1.  Hazard regression for interval-censored data with penalized spline.

Authors:  Tianxi Cai; Rebecca A Betensky
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  Infectious complications in polymyositis and dermatomyositis: a series of 279 patients.

Authors:  Isabelle Marie; Jean-François Ménard; Eric Hachulla; Patrick Chérin; Olivier Benveniste; Kiet Tiev; Pierre-Yves Hatron
Journal:  Semin Arthritis Rheum       Date:  2010-11-02       Impact factor: 5.532

3.  PCP chemoprophylaxis is essential for lymphopenic dermatomyositis patients treated with immunomodulators.

Authors:  Petros Efthimiou; Hiren Pokharna; Manil Kukar; Karen Hennessey
Journal:  Muscle Nerve       Date:  2011-04-12       Impact factor: 3.217

4.  Infections in polymyositis and dermatomyositis: analysis of 192 cases.

Authors:  I-Jung Chen; Wen-Pin Tsai; Yeong-Jian Jan Wu; Shue-Fen Luo; Huei-Huang Ho; Lieh-Bang Liou; Ji-Yih Chen; Chang-Fu Kuo; Hsiao-Chun Chang; Chung-Han Yang; Kuang-Hui Yu
Journal:  Rheumatology (Oxford)       Date:  2010-09-13       Impact factor: 7.580

5.  Guidelines for treatment of autoimmune neuromuscular transmission disorders.

Authors:  G O Skeie; S Apostolski; A Evoli; N E Gilhus; I Illa; L Harms; D Hilton-Jones; A Melms; J Verschuuren; H W Horge
Journal:  Eur J Neurol       Date:  2010-04-12       Impact factor: 6.089

6.  Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series.

Authors:  B Hernández-Cruz; J Sifuentes-Osornio; S Ponce-de-León Rosales; A Ponce-de-León Garduño; E Díaz-Jouanen
Journal:  Clin Exp Rheumatol       Date:  1999 May-Jun       Impact factor: 4.473

Review 7.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

8.  Autoimmunity as a predisposition for infectious diseases.

Authors:  Mohan S Maddur; Janakiraman Vani; Sébastien Lacroix-Desmazes; Srinivas Kaveri; Jagadeesh Bayry
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

9.  Salmonella brain abscess in a patient on chronic azathioprine therapy for myasthenia gravis: report of an unusual case and review of literature in the postantibiotic era.

Authors:  Chetan R Soni; Gyanendra Kumar; Pradeep C Bollu; Pradeep Sahota; N Scott Litofsky
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

Review 10.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more
  6 in total

1.  Pneumocystis jirovecii Pneumonia in Neurologic Disorders: Is Prophylaxis Necessary?

Authors:  Tiffany Pike-Lee; Sana Syed; Mary Alissa Willis; Yuebing Li
Journal:  Neurol Clin Pract       Date:  2021-06

2.  Are we aiming to miss in translational autoimmunity treatments?

Authors:  Gisela M Vaitaitis; David H Wagner
Journal:  F1000Res       Date:  2018-11-06

3.  Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.

Authors:  Sasha A Živković; Gregory Gruener; Pushpa Narayanaswami
Journal:  Muscle Nerve       Date:  2021-01-27       Impact factor: 3.217

4.  Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.

Authors:  Stephen Johnson; Nakul Katyal; Naureen Narula; Raghav Govindarajan
Journal:  Med Sci Monit       Date:  2021-10-28

Review 5.  Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis.

Authors:  Christopher A Mecoli; Sonye K Danoff
Journal:  Curr Rheumatol Rep       Date:  2020-02-05       Impact factor: 4.686

6.  Sepsis Mortality Is high in Patients With Connective Tissue Diseases Admitted to the Intensive Care Unit (ICU).

Authors:  Marco Krasselt; Christoph Baerwald; Sirak Petros; Olga Seifert
Journal:  J Intensive Care Med       Date:  2021-02-25       Impact factor: 3.510

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.